Migraine - Triptans Drug Quantity Management Policy - Per Rx
Defines quantity limits and coverage approach for triptan products (injectable, oral, combination, nasal) used for acute migraine and cluster headache across Cigna-administered health benefit plans.
New quantity limits of 9 Symbravo tablets per dispensing at retail and 27 per dispensing at home delivery were added, with override criteria for intermittent acute migraine.
Zolmitriptan 5 mg tablets and Zomig-ZMT override criteria added to approve 18 tablets per retail dispensing or 54 per home delivery for cluster headache diagnosis.
Override criteria for sumatriptan subcutaneous injections and Zembrace Symtouch updated to reflect approvals in mL rather than number of devices.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.